Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
38.50
-0.02 (-0.05%)
At close: Jul 10, 2025, 4:00 PM
38.90
+0.40 (1.04%)
After-hours: Jul 10, 2025, 5:40 PM EDT
Revolution Medicines Employees
Revolution Medicines had 534 employees as of December 31, 2024. The number of employees increased by 156 or 41.27% compared to the previous year.
Employees
534
Change (1Y)
156
Growth (1Y)
41.27%
Revenue / Employee
n/a
Profits / Employee
-$1,306,191
Market Cap
7.17B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RVMD News
- 1 day ago - Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates - GlobeNewsWire
- 10 days ago - Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors - GlobeNewsWire
- 10 days ago - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors - Business Wire
- 16 days ago - Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug - Reuters
- 16 days ago - Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers - GlobeNewsWire
- 17 days ago - Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations - GlobeNewsWire
- 21 days ago - Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History - Seeking Alpha
- 2 months ago - Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer - GlobeNewsWire